| Therapeutics |
| Autologous cultured chondrocytes (Carticel)* | Repair of cartilaginous defects of the femoral condyle |
| Becaplermin (Regranex Gel 0.01%)* | Once-daily treatment of diabetic ulcers |
| Coagulation factor IX recombinant (BeneFIX)*† | Control and prevention of hemorrhagic episodes of hemophilia B |
| Daclizumab (Zenapax)*† | Prevention of acute renal allograft rejection |
| Interferon alfacon-1 (Infergan)* | Treatment of chronic hepatitis C |
| Oprelvekin (rhIL11; Neumega)*† | Prevention of severe thrombocytopenia following chemotherapy |
| Rituximab (Rituxan)*† | Treatment of relapsed or refractory low-grade or follicular, B-cell non-Hodgkin's lymphoma |
| Vaccine |
| Diphtheria and tetanus toxoids and acellular pertussis (DTaP) adsorbed vaccine (Infanrix) | Immunization of infants and children, 6 weeks to 7 years of age, against diphtheria, tetanus and pertussis |
| Rabies vaccine (RabAvert) | Immunization of children and adults against rabies |